Psyched Wellness (CSE: PSYC) has begun yet another study related to that of the Amanita Muscaria mushroom. The latest research to be conducted by the firm will focus on the therapeutic values of muscimol, an active compound within the fungi, for antioxidant and anti-inflammatory purposes.
The study will test for these properties via what is referred to as “nerve derived immunity and neuroprotective modulation models,” with the study to be reportedly led by Brian Tancowny. Tancowny, whom currently sits on the firms advisory board, has over 25 years of experience in the field of research and development with government, academic and private sector partners.
Tancowny will focus on the effectiveness of muscimol for the properties, with preliminary work to focus on identifying the role in health modulation of oxidative stress and inflammation. The study will then focus on what is referred to as the potential neuroprotective effects of the compound. The results are significant for the company, given that antioxidants have been shown to reduce the risk of many serious diseases such as certain cancers as well as heart disease.
“This initial preliminary study will provide more insight into the potential health and wellness properties of the active compound muscimol of the Amanita Muscaria mushroom, which may lead into advanced preclinical areas of study for further work into a natural therapeutic agent.”
Brian Tancowny, Advisor To Psyched Wellness
Psyched Wellness last traded at $0.27 on the CSE.
FULL DISCLOSURE: Psyched Wellness is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Psyched Wellness on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
